Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Seattle Genetics Halts Enrollment in Vadastuximab Talirine Trials

Seattle Genetics said today it was halting enrollment in all clinical trials assessing its cancer candidate vadastuximab talirine (SGN-CD33A). ...

Forward this item to a colleague:


(Separate multiple addresses by commas)